Top Industry Leaders in the Retinal Drugs Market
Latest Retinal Drugs Companies Update
Sobi receives EMA approval for Igalolix (pegvoribate) novel therapy offers a potentially transformative treatment for adults with moderate to severe Hemophilia A with inhibitors, providing prolonged protection against bleeding through a new mechanism of action.
BioMarin initiates Phase 3 trial for valoctocogene roxadustat A (ROX-A ViiV) gene therapy aims to provide a potential cure for Hemophilia A by addressing the underlying genetic defect, holding immense promise for long-term management of the condition.
Alnylam Pharmaceuticals announces positive Phase 3 results for lumasiran RNA interference (RNAi) therapy demonstrates efficacy in preventing bleeding episodes in Hemophilia A patients, potentially offering another innovative treatment option.
Roche acquires Tropic Biosciences acquisition strengthens Roche's hemophilia portfolio with Tropic's innovative gene therapy candidate for Hemophilia B, solidifying their position in this area.
Pfizer partners with Sanofi collaboration focuses on developing novel gene therapies for both Hemophilia A and B, combining their expertise and resources to accelerate research and development efforts.
Bayer collaborates with Spark Therapeutics partnership aims to explore potential synergies between Bayer's existing hemophilia treatments and Spark's gene therapy technologies, striving for comprehensive management solutions.
List of Retinal Drugs Key Companies in the Market
- Bayer AG
- Alcon Inc.
- Alimera Sciences Inc.
- Bausch Health Co Inc.
- Bristol Myers Squibb Co.
- Hoffmann La Roche Ltd.
- Kubota Corp.
- MeiraGTx Holdings Plc
- Novartis AG
- Ocular Therapeutix Inc.
- Oxurion NV
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- REGENXBIO Inc
- Sanofi SA